Masanori Watanabe Selected Research

Enteropeptidase

1/2023	An Exploratory Randomized Trial of SCO-792, an Enteropeptidase Inhibitor, in Patients With Type 2 Diabetes and Albuminuria.
1/2022	Design, Synthesis, and Biological Evaluation of a Novel Series of 4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity.
1/2021	Enteropeptidase inhibition improves kidney function in a rat model of diabetic kidney disease.
1/2021	Enteropeptidase inhibitor SCO-792 effectively prevents kidney function decline and fibrosis in a rat model of chronic kidney disease.
1/2021	Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice.
10/2019	SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masanori Watanabe Research Topics

Disease

13	Neoplasms (Cancer) 01/2024 - 08/2002
8	Obesity 01/2022 - 06/2014
7	Stomach Neoplasms (Stomach Cancer) 12/2023 - 02/2006
6	Type 2 Diabetes Mellitus (MODY) 01/2023 - 01/2017
5	Pain (Aches) 01/2015 - 01/2004
4	Infections 09/2023 - 11/2005
4	Inflammation (Inflammations) 01/2022 - 06/2014
4	Fibrosis (Cirrhosis) 11/2021 - 10/2020
4	Body Weight (Weight, Body) 10/2020 - 01/2019
4	Postoperative Pain 01/2017 - 01/2004
3	Insulin Resistance 01/2023 - 10/2019
3	Chronic Renal Insufficiency 11/2021 - 06/2014
3	Hemorrhage 09/2021 - 07/2003
3	Carcinoma (Carcinomatosis) 01/2017 - 06/2007
2	Esophageal Neoplasms (Esophageal Cancer) 09/2023 - 10/2007
2	Albuminuria 01/2023 - 01/2021
2	Hernia (Hernias) 01/2022 - 04/2019
2	Non-alcoholic Fatty Liver Disease 11/2021 - 10/2020
2	Hypoglycemia (Reactive Hypoglycemia) 10/2021 - 11/2017
2	Sepsis (Septicemia) 01/2020 - 01/2017
2	Flushing 12/2019 - 01/2018
2	Inguinal Hernia (Direct Inguinal Hernia) 04/2019 - 02/2008
2	Wounds and Injuries (Trauma) 01/2017 - 01/2015
2	Pneumoperitoneum 10/2009 - 01/2004
2	Colorectal Neoplasms (Colorectal Cancer) 02/2005 - 08/2002
1	Enteritis 01/2024
1	Leriche Syndrome 01/2024
1	Anastomotic Leak 09/2023
1	Tremor (Tremors) 01/2023
1	Hepatocellular Carcinoma (Hepatoma) 02/2022
1	Internal Hernia 01/2022
1	Hyperplasia 01/2022
1	Protein-Losing Enteropathies (Protein-Losing Enteropathy) 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Hypertrophy 11/2021
1	Hyperglycemia 10/2021
1	Diverticular Diseases 09/2021
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021
1	Chronic Disease (Chronic Diseases) 01/2021

Drug/Important Bio-Agent (IBA)

8	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 06/2017
6	EnteropeptidaseIBA 01/2023 - 10/2019
5	N- (((3S)- 6- ((4- carbamimidamidobenzoyl)oxy)- 2,3- dihydro- 1- benzofuran- 3- yl)acetyl)- L- aspartic acid hydrateIBA 01/2023 - 10/2019
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2002
4	SCO-267IBA 10/2021 - 01/2019
3	Insulin (Novolin)FDA Link 01/2023 - 06/2007
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 02/2007
3	Messenger RNA (mRNA)IBA 10/2020 - 08/2002
2	Amino Acids FDA Link 01/2023 - 10/2020
2	Hormones (Hormone)IBA 10/2021 - 01/2019
2	Therapeutic UsesIBA 01/2021 - 01/2021
2	LipidsIBA 10/2019 - 01/2018
2	Analgesics (Analgesic Drugs)IBA 01/2015 - 03/2005
2	Fentanyl (Sublimaze)FDA LinkGeneric 09/2008 - 03/2005
2	keratinocyte growth factor receptorIBA 02/2006 - 02/2005
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 03/2005 - 01/2004
1	Cisplatin (Platino)FDA LinkGeneric 12/2023
1	Docetaxel (Taxotere)FDA Link 12/2023
1	somatostatin receptor 5IBA 01/2023
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2023
1	Pyruvate Dehydrogenase Acetyl-Transferring KinaseIBA 02/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 02/2022
1	Pyruvic Acid (Pyruvate)IBA 02/2022
1	CollagenIBA 01/2022
1	4-guanidinobenzoateIBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	EstersIBA 01/2022
1	Acetyl-CoA CarboxylaseIBA 11/2021
1	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 11/2021
1	Coenzyme A (CoA)IBA 11/2021
1	Adenosine Triphosphate (ATP)IBA 11/2021
1	Triglycerides (Triacylglycerol)IBA 11/2021
1	AnticoagulantsIBA 09/2021
1	CoagulantsIBA 09/2021
1	Warfarin (Coumadin)FDA LinkGeneric 09/2021
1	Immunoglobulin A (IgA)IBA 01/2021
1	Cysteine (L-Cysteine)FDA Link 01/2021
1	Appetite Depressants (Anorectics)IBA 01/2021

Therapy/Procedure

5	Gastrectomy 07/2012 - 01/2007
4	Therapeutics 12/2023 - 06/2007
3	Catheters 09/2023 - 07/2003
3	Oral Administration 01/2023 - 11/2017
3	Laparoscopic Cholecystectomy 01/2015 - 01/2004
3	Epidural Anesthesia 02/2014 - 01/2004
2	Minimally Invasive Surgical Procedures 01/2024 - 01/2024
2	Surgical Instruments (Clip) 01/2023 - 01/2015
2	Laparotomy 01/2022 - 01/2011
2	Glycemic Control 10/2021 - 01/2019
2	Blood Transfusion (Blood Transfusions) 09/2021 - 06/2014
2	Pancreaticoduodenectomy 01/2017 - 07/2012
2	Length of Stay 01/2017 - 02/2008
2	Conservative Treatment 01/2017 - 02/2007
2	Operative Surgical Procedures 06/2014 - 01/2013
2	Colectomy 07/2012 - 08/2010
2	Pancreatectomy 07/2012 - 01/2009
2	Lymph Node Excision (Lymph Node Dissection) 11/2010 - 01/2007
2	Analgesia 09/2008 - 01/2004
2	General Anesthesia 02/2007 - 01/2004
1	Nutritional Support (Artificial Feeding) 09/2023
1	Esophagectomy 09/2023
1	Aftercare (After-Treatment) 01/2022